Men in Torbay and South Devon diagnosed with early-stage localised prostate cancer are being offered a brand new treatment designed to help manage the condition.

Stereotactic ablative radiotherapy (SABR) delivers targeted, higher-dose radiotherapy directly to a tumour, helping to reduce the risk of cancer spreading or returning.

The treatment is typically delivered in five doses, known as fractions, over two weeks.

This compares with 20 doses using standard external beam radiotherapy. Stephen Dwyer-Lapthorne is the first man in Torbay and South Devon to receive SABR after being diagnosed with localised prostate cancer in October 2025.

He said: "I was so pleased to be offered SABR at Torbay Hospital.

"I only have one session (fraction) left of the planned five sessions, and right now, I don't feel anything other than slightly fatigued, although I'm expecting potential side effects later."

"I'm meeting with the review radiographer once my treatment has finished for another PSA test before my six-week follow-up appointment."

NHS England approved the use of SABR across the country in June to treat prostate cancer, which is diagnosed in around 55,000 men in the UK each year.

Naomi Hopkins, Head of Radiotherapy at Torbay and South Devon NHS Foundation Trust, said the national rollout would give more patients access to the treatment. She added: "This national rollout is fantastic news for patients, giving Stephen and thousands of other men with a low or intermediate risk of prostate cancer access to SABR."

"We are delighted that we are delivering prostate SABR locally, helping patients receive their treatment closer to home without needing to travel far."

Torbay and South Devon NHS Foundation Trust said the treatment would allow eligible patients to receive SABR locally rather than travelling further for care.

The trust provides acute services through Torbay Hospital and five community hospitals.